Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 54 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
Di | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Di | TransCode Therapeutics Announces $10M Stock And Warrant Offering | 1 | RTTNews | ||
Mo | TransCode Therapeutics stock slides after announces to raise $10M securities offering | 5 | Seeking Alpha | ||
21.03. | TransCode Therapeutics Stock Surges 85% | 15 | RTTNews | ||
21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 471 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
13.03. | TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy | 5 | RTTNews | ||
13.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial | 145 | PR Newswire | Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3
No significant... ► Artikel lesen | |
TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
25.02. | TransCode Therapeutics, Inc. Announces Results of Special Meeting | 534 | PR Newswire | BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more... ► Artikel lesen | |
25.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
06.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial | 241 | PR Newswire | No significant safety or dose limiting toxicities reported
PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Feb.... ► Artikel lesen | |
24.01. | TransCode Therapeutics Shares Are Surging Today: What's Going On? | 15 | Benzinga.com | ||
07.01. | TransCode Therapeutics regains compliance with Nasdaq | 5 | Seeking Alpha | ||
20.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
18.12.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | 188 | PR Newswire | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
06.12.24 | Transcode Therapeutics, Inc. - S-1, General form for registration of securities | 11 | SEC Filings | ||
02.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.12.24 | Why TransCode Therapeutics (RNAZ) Stock Is Diving | 8 | Benzinga.com | ||
02.12.24 | TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 | 2 | Seeking Alpha | ||
29.11.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split | 306 | GlobeNewswire (Europe) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 86,90 | -1,36 % | Bayer, Vidac Pharma, BioNTech - Niederschläge und neue Maßstäbe | Glyphosat und kein Ende. Die Übernahme des US-amerikanischen Agrarunternehmens Monsanto durch Bayer im Jahr 2018 entwickelt sich weiterhin zum Milliardengrab, erneut entschied ein Gericht gegen die... ► Artikel lesen | |
QIAGEN | 36,800 | -0,11 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
NOVAVAX | 6,433 | -0,66 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,617 | +1,31 % | Palatin Techs Aktie: Positive Signale setzen! | Biotechnologieunternehmen erreicht wichtigen regulatorischen Durchbruch mit oralem Wirkstoff gegen genetisch bedingte Fettleibigkeit und verzeichnet Kursanstieg Palatin Technologies, Inc. (NYSE American:... ► Artikel lesen | |
BRAIN BIOTECH | 2,450 | +1,24 % | EQS-News: BRAIN Biotech AG: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Hauptversammlung
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
18.03.2025 / 16:45 CET/CEST
Für... ► Artikel lesen | |
ORGANOVO | 2,650 | 0,00 % | Organovo, Inc.: Organovo Provides Business Update | SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,550 | -3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,900 | -3,97 % | COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents | Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified... ► Artikel lesen | |
GENMAB | 182,20 | +0,33 % | Genmab A/S: TIVDAK (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy | TIVDAK is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in Japan Approval is based on results from the global Phase 3... ► Artikel lesen | |
XOMA ROYALTY | 19,200 | +2,13 % | The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts | ||
T2 BIOSYSTEMS | 0,089 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 1,320 | +0,76 % | Phio Pharmaceuticals Corp.: American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting | Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA... ► Artikel lesen | |
MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
ORAGENICS | 0,223 | -0,98 % | Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress | SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today... ► Artikel lesen | |
LADRX | - | - | LadRx Corp - 10-K, Annual Report |